Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Bearish
2
Neutral
6
Bullish
6
Bearish
8
Neutral
6
Bullish
32
Bearish
6
Neutral
0
Bullish
26
Discovery themes featuring this stockDiscovery themes featuring this stock
Lincoln Pharmaceuticals Limited is an India-based manufacturer and marketer of pharmaceutical formulations across anti-infective, respiratory, gynecology, cardio/CNS, antidiabetic and other therapy areas, operating multiple manufacturing lines including tablets, injectables and parenterals and focused on branded generics plus export markets.
Q3 FY26 headline performance strengthened: standalone quarter revenue INR 166.32 crore, EBITDA INR 38.74 crore and PAT INR 28.60 crore, while management reaffirmed a mid-teens EBITDA margin target (15% base, targeting up to 18%) and a long-term INR 1,000 crore revenue aspiration with a small timing caveat.
Exports and regulated-market progress are driving strategic momentum: Health Canada approvals across six lines and CDMO/CMO commercialisation delivering roughly USD 3–5 million this year, with management citing ~23–25 projects in process and export revenues around INR 400 crore.
Operationally, Lincoln is completing a dedicated R&D centre and has commissioned the Mehsana Cephalosporin block that has crossed breakeven; management expects the existing site can expand utilization by another c.15–20% while larger growth will need inorganic additions or a new greenfield unit.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,354 Cr
Low Risk
15.4
34.2
0.2
1.9
679.45
439.95
Sales CAGR
Profit CAGR
ROE
ROCE
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Lincoln Pharmaceuticals Ltd (LINCOLN) is currently trading at 666.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Lincoln Pharmaceuticals Limited is an India-based manufacturer and marketer of pharmaceutical formulations across anti-infective, respiratory, gynecology, cardio/CNS, antidiabetic and other therapy areas, operating multiple manufacturing lines including tablets, injectables and parenterals and focused on branded generics plus export markets. Q3 FY26 headline performance strengthened: standalone quarter revenue INR 166.32 crore, EBITDA INR 38.74 crore and PAT INR 28.60 crore, while management reaffirmed a mid-teens EBITDA margin target (15% base, targeting up to 18%) and a long-term INR 1,000 crore revenue aspiration with a small timing caveat. Exports and regulated-market progress are driving strategic momentum: Health Canada approvals across six lines and CDMO/CMO commercialisation delivering roughly USD 3–5 million this year, with management citing ~23–25 projects in process and export revenues around INR 400 crore. Operationally, Lincoln is completing a dedicated R&D centre and has commissioned the Mehsana Cephalosporin block that has crossed breakeven; management expects the existing site can expand utilization by another c.15–20% while larger growth will need inorganic additions or a new greenfield unit.
Over the past 52 weeks, Lincoln Pharmaceuticals Ltd has traded between a low of ₹439.95 and a high of ₹679.45. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Lincoln Pharmaceuticals Ltd has a market capitalization of approximately 1,354.01. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Lincoln Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 15.41 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,354.01 Cr, Lincoln Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Lincoln Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Lincoln Pharmaceuticals Ltd is 15.41. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
2329.00 | 1,450 Cr | 41.32 | 4.83 | 0.07 | 6.89 | 8.00 | 7.25 | ||
1429.05 | 1,403 Cr | 34.27 | 4.15 | 0.42 | 12.98 | 9.93 | 6.29 | ||
13.72 | 1,383 Cr | 20.05 | 3.65 | 0.00 | 16.66 | 22.00 | 15.12 | ||
615.00 | 1,354 Cr | 15.41 | 1.89 | 0.27 | 11.18 | 15.34 | 10.28 | ||
926.00 | 1,346 Cr | 17.63 | 2.26 | 0.00 | 10.66 | 13.99 | 9.93 | ||
1336.00 | 1,340 Cr | 32.32 | 5.88 | 0.00 | 18.96 | 18.07 | 8.50 | ||
1820.00 | 1,309 Cr | 40.06 | 5.11 | 0.03 | 22.85 | 26.16 | 7.04 | ||
| Median: 7 Co. | — | 1336.00 | 1,354 Cr | 32.32 | 4.15 | 0.03 | 12.98 | 15.34 | 8.50 |
